In an exploratory, randomised phase 2 study (NCT05332366), 30 women with FFA were randomised 1:1 to delgocitinib cream 20 mg/g twice daily or a matching vehicle over 12 weeks [1]. The primary endpoint was defined as change from baseline to week 12 in IFN-γ, CXCL9, and CXCL10. At baseline, the study cohort had a mean age of 64.4 years, the Lichen Planopilaris Activity Index (LPPAI) was 2.79, and FFASS 12.14.
RNA sequencing and Th1 biomarker assessment detected numeric reductions in IFN-γ, CXCL10, and a statistically significant decrease in CXCL9 (P<0.05). Prof. Maryanne Senna (Harvard Medical School, MA, USA) said that this suggested an attenuation of key inflammatory scalp biomarkers in FFA by delgocitinib cream. “Transcriptomic analysis showed that delgocitinib lesions had a 4% improvement towards non-lesional scalp skin compared with the vehicle-treated patients who actually had 33% worsening of their transcriptomic profile,” she added. At week 12, the FFASS decrease was significantly superior to the vehicle (P=0.023) and LPPAI showed numerically greater changes on delgocitinib.
In an open-label extension phase until week 24, all participants continued on the study drug. An exploratory analysis found hair regrowth to some extent for all participants on delgocitinib at week 24. An average of 6.9 new hairs was observed in trichoscopy of 1 cm2 scalp of the participants treated with delgocitinib at week 12, in contrast to a loss of 11.1 hairs in the vehicle group.
The safety assessment deemed delgocitinib cream in FAA well tolerated with only 1 treatment-related adverse event (i.e. moderate hand dermatitis) in the vehicle group.
“If we could recapitulate this data in larger clinical trials, this could be potentially a promising therapeutic option for this patient population,” Prof. Senna concluded
- Senna MM, et al. Randomized vehicle-controlled clinical trial with the topical JAK inhibitor delgocitinib in patients with frontal fibrosing alopecia demonstrates biomarker and clinical efficacy. D3T01.4F, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff MPH
Posted on
Previous Article
« ESMO 2024 Highlights Podcast Next Article
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis »
« ESMO 2024 Highlights Podcast Next Article
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
December 20, 2018
AD sleep disturbance, antihistamines and osteoporosis
August 26, 2019
Statin use elevates risk of eczema and atopic dermatitis
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com